Summit Therapeutics Inc

General ticker "SMMT" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $13.3B

Summit Therapeutics Inc follows the US Stock Market performance with the rate: 51.0%.

Estimated limits based on current volatility of 3.4%: low 17.57$, high 18.82$

Factors to consider:

  • Current price 401.3% above estimated high
  • Earnings for 9 months up through Q3 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [1.51$, 3.72$]
  • 2024-12-30 to 2025-12-30 estimated range: [1.20$, 3.13$]

Financial Metrics affecting the SMMT estimates:

  • Negative: Non-GAAP EPS, $ of -0.15 <= 0.10
  • Negative: Operating profit margin, % of -99.84 <= 1.03
  • Negative: negative Net income
  • Negative: Operating cash flow per share per price, % of -5.10 <= 2.35
  • Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85

Similar symbols

Short-term SMMT quotes

Long-term SMMT plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $22.78MM $15.12MM $1.00MM
Operating Expenses $108.96MM $87.21MM $610.65MM
Operating Income $-86.19MM $-72.09MM $-609.65MM
Non-Operating Income $-2.42MM $-6.69MM $-5.28MM
Interest Expense $0.28MM $4.40MM $16.46MM
R&D Expense $85.35MM $52.00MM $59.47MM
Income(Loss) $-88.60MM $-78.78MM $-614.93MM
Profit(Loss) $-88.60MM $-78.78MM $-614.93MM
Stockholders Equity $83.28MM $126.65MM $77.69MM
Inventory $7.16MM $301.50MM $0.00MM
Assets $113.37MM $664.17MM $202.95MM
Operating Cash Flow $-72.59MM $-41.58MM $-76.76MM
Capital expenditure $0.31MM $0.62MM $0.13MM
Investing Cash Flow $-0.31MM $-0.62MM $-587.77MM
Financing Cash Flow $77.92MM $620.24MM $86.51MM
Earnings Per Share* $-0.93 $-0.38 $-0.99

* EPS are Split Adjusted, recent splits may be reflected with a delay.